Osteomet Drug Interactions

There have been no specific drug-drug interaction studies conducted with zoledronic acid. Since zoledronic acid is approximately 22% bound to plasma proteins in vitro and does not inhibit microsomal CYP450 enzymes, interactions resulting from displacement of highly protein-bound drugs are unlikely. Moreover, zoledronic acid is not metabolized and is excreted into the urine as the intact drug in vivo.
Zoledronic acid has been administered concomitantly with the following drugs without clinically apparent interactions: Anticancer agents, diuretics, antibiotics and analgesics.
Loop Diuretics: Concomitant use may result in increased risk of hypocalcemia.
Aminoglycosides: Concomitant administration may result in possible additive effect in lowering serum calcium concentrations for prolonged periods.
Nephrotoxic Drugs (e.g., aminoglycosides, other antineoplastic agents, ASA, NSAIDs) or drugs that significantly impact renal function (e.g., diuretics, ACE inhibitors): Zoledronic acid should be used with caution since concomitant administration may result in increased risk of renal impairment.
Thalidomide: The risk of renal insufficiency may be increased when zoledronic acid is used concomitantly with thalidomide especially in patients with multiple myeloma.